We use cookies to customise content for your subscription and for analytics.
If you continue to browse Lexology, we will assume that you are happy to receive all our cookies. For further information please read our Cookie Policy.

Search

Refine your search

Content type
Tags
Firm name
Author
Jurisdiction

297 results found

Article

Skadden Arps Slate Meagher & Flom LLP | USA | 15 May 2017

First Circuit Affirms Dismissal of Securities Class Action Against Biogen Inc.

On May 12, 2017, the U.S. Court of Appeals for the First Circuit affirmed dismissal of the putative securities class action In re Biogen Inc

Article

Pierce Atwood LLP | USA | 30 Nov 2016

First Circuit Affirms Tough Standard for Alleging Securities Fraud; Revives One Claim Against Local Drug Maker

On November 28, 2016, the First Circuit upheld the dismissal of all but one of the class action securities fraud claims against Cambridge, MA drug

Article

Baker & Hostetler LLP | USA | 13 Jun 2014

Genzyme First Circuit decision

In a huge victory for Massachusetts-based biologics manufacturer Genzyme Corporation, the First Circuit Court of Appeals on June 5, 2014 affirmed the

Article

Winston & Strawn LLP | USA | 9 Jun 2014

Financial services update June 9 2014 judicial developments

On June 5th, the First Circuit affirmed the dismissal of plaintiffs' securities fraud lawsuit. The appellate court found that Genzyme had no duty to

Article

Day Pitney LLP | USA | 3 Sep 2013

White collar roundup - September 2013

In United States v. DiMasi, the U.S. Court of Appeals for the First Circuit, with Associate Justice (Ret.) David H. Souter sitting by designation

Article

Winston & Strawn LLP | USA | 11 Feb 2013

Securities fraud claims against drug firm are reinstated

On February 4th, the United States Court of Appeals for the First Circuit partially reinstated securities fraud claims stemming from a secondary

Article

Sheppard Mullin Richter & Hampton LLP | USA | 6 Aug 2012

Case study: In re Boston Scientific

In In re Boston Scientific Corp. Securities Litigation (1st Cir. July 12, 2012), the United States Court of Appeals for the First Circuit affirmed the dismissal of a securities class action lawsuit against Boston Scientific Corporation (the “BSC”).

Article

Sheppard Mullin Richter & Hampton LLP | USA | 27 Jul 2012

First Circuit upholds dismissal of securities fraud action based upon immateriality of allegedly omitted information

In In re Boston Scientific Corp. Securities Litigation, 2012 WL 2849660 (1st Cir. July 12, 2012), the United States Court of Appeals for the First Circuit affirmed the dismissal of a securities class action lawsuit against Boston Scientific Corporation (the “BSC”).

Article

Latham & Watkins LLP | USA | 3 Jul 2012

District Court ruling paves the way for more “negligent securities fraud” enforcement actions under Sections 17(a)(2) and (3) of the Securities Act

Last year, the Wall Street Journal predicted that the SEC “could file more civil cases in which defendants are accused of negligence only, rather than harder-to-prove charges of intentional wrongdoing or recklessness”.

Article

Kramer Levin Naftalis & Frankel LLP | USA | 15 Jun 2012

Supreme Court grants certiorari to address question whether plaintiffs must prove materiality prior to class certification in federal securities fraud actions

For over 20 years, the “fraud on the market” theory under Basic Inc. v. Levinson, 485 U.S. 224 (1988), has been a key tool for plaintiffs in class action securities fraud litigation.

Previous page 1 2 3 ...